A novel Nrf2 activator, RS9, protected the brain from ischemia–reperfusion injury.
The efficacy of post-onset treatment is because of rapid Nrf2 activation by RS9.
RS9 attenuated not only oxidative stress but also neuroinflammation.
RS9 protected the brain in both the acute and sub-acute phase of ischemia.